hether subclinical hypothyroidism is clinically important and should be treated remains controversial. Studies have differed in their fi ndings, and although most have found this condition to be associated with a variety of adverse outcomes, large randomized controlled trials are needed to clearly demonstrate its clinical impact in various age groups and the benefi t of levothyroxine therapy.
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Currently, the best practical approach is to base treatment decisions on the magnitude of elevation of thyroid-stimulating hormone (TSH) and whether the patient has thyroid autoantibodies and associated comorbid conditions.
■ HIGH TSH, NORMAL FREE T 4 LEVELS
Subclinical hypothyroidism is defi ned by elevated TSH along with a normal free thyroxine (T 4 ). 1 The hypothalamic-pituitary-thyroid axis is a balanced homeostatic system, and TSH and thyroid hormone levels have an inverse loglinear relation: if free T 4 and triiodothyronine (T 3 ) levels go down even a little, TSH levels go up a lot. 2 TSH secretion is pulsatile and has a circadian rhythm: serum TSH levels are 50% higher at night and early in the morning than during the rest of the day. Thus, repeated measurements in the same patient can vary by as much as half of the reference range. 3 
■ WHAT IS THE UPPER LIMIT OF NORMAL FOR TSH?
In favor of a lower upper limit: the distribution of serum TSH levels in the healthy general population does not seem to be a typical bell-shaped Gaussian curve, but rather has a tail at the high end. Some argue that some of the individuals with values in the upper end of the normal range may actually have undiagnosed hypothyroidism and that the upper 97.5th percentile cutoff would be 2.5 mIU/L if these people were excluded. 4 Also, TSH levels higher than 2.5 mIU/L have been associated with a higher prevalence of antithyroid antibodies and a higher risk of clinical hypothyroidism. 5 On the other hand, lowering the upper limit of normal to 2.5 mIU/L would result in 4 times as many people receiving a diagnosis of subclinical hypothyroidism, or 22 to 28 million people in the United States. 4, 6 Thus, lowering the cutoff may lead to unnecessary therapy and could even harm from overtreatment.
Another argument against lowering the upper limit of normal for TSH is that, with age, serum TSH levels shift higher. 7 The third National Health and Nutrition Education Survey (NHANES III) found that the 97.5th percentile for serum TSH was 3.56 mIU/L for age group 20 to 29 but 7.49 mIU/L for octogenarians. 7, 8 It has been suggested that the upper limit of normal for TSH be adjusted for age, race, sex, and iodine intake. 3 Currently available TSH reference ranges are not adjusted for these variables, and there is not enough evidence to suggest age-appropriate ranges, 9 although higher TSH cutoffs for treatment are advised in elderly patients. 10 Interestingly, higher TSH in older people has been linked to lower mortality rates in some studies.
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Authors of the NHANES III 8 and Hanford Thyroid Disease study 12 have proposed a cutoff of 4.1 mIU/L for the upper limit of normal for serum TSH in patients with negative antithyroid antibodies and normal fi ndings on thyroid ultrasonography.
■ SUBCLINICAL HYPOTHYROIDISM IS COMMON
In different studies, the prevalence of subclinical hypothyroidism has been as low as 4% and as high as 20%. 1, 8, 13 The prevalence is higher in women and increases with age. 8 It is higher in iodine-suffi cient areas, and it increases in iodine-defi cient areas with iodine supplementation.
14 Genetics also plays a role, as subclini- 
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The upper limit of normal for serum TSH is controversial cal hypothyroidism is more common in white people than in African Americans. 8 A diffi culty in estimating the prevalence is the disagreement about the cutoff for TSH, which may differ from that in the general population in certain subgroups such as adolescents, the elderly, and pregnant women. 10, 15 ■ A VARIETY OF CAUSES
The most common cause of subclinical hypothyroidism, accounting for 60% to 80% of cases, is Hashimoto (autoimmune) thyroiditis, 2 in which thyroid peroxidase antibodies are usually present. 2, 16 Other causes include suboptimal treatment of hypothyroidism due to other reasons such as thyroidectomy, radioactive iodine treatment, external radiation, infi ltrative diseases (eg, amyloidosis, sarcoidosis, hemochromatosis), and drugs (eg, iodinated contrast, amiodarone, lithium, tyrosine kinase inhibitors) ( Table 1) . 1, 2, 16 Also important to rule out are false-positive elevations due to substances that interfere with TSH assays (eg, heterophile antibodies, rheumatoid factor, biotin, macro-TSH); reversible causes such as the recovery phase of euthyroid sick syndrome; subacute, painless, or postpartum thyroiditis; central hypo-or hyperthyroidism; and thyroid hormone resistance.
■ SUBCLINICAL HYPOTHYROIDISM CAN RESOLVE OR PROGRESS
"Subclinical" suggests that the disease is in its early stage, with changes in TSH already apparent but decreases in thyroid hormone levels yet to come. 17 And indeed, subclinical hypothyroidism can progress to overt hypothyroidism, 18 although it has been reported to resolve spontaneously in half of cases within 2 years, 19 typically in patients with TSH values of 4 to 6 mIU/L. 20 The rate of progression to overt hypothyroidism is estimated to be 33% to 35% over 10 to 20 years of follow-up. 18 The risk of progression to clinical disease is higher in patients with thyroid peroxidase antibody, reported as 4.3% per year compared with 2.6% per year in those without this antibody. 20, 21 In one study, the risk of developing overt hypothyroidism in those with subclinical hypothyroidism increased from 1% to 4% with doubling of the TSH. 21 Other risk factors for progression to hypothyroidism include female sex, older age, goiter, neck irradiation or radioactive iodine exposure, and high iodine intake.
18,22 Figure 1 shows the natural history of subclinical hypothyroidism.
■ GUIDELINES FOR SCREENING DIFFER
Guidelines differ on screening for thyroid disease in the general population, owing to lack of large-scale randomized controlled trials showing treatment benefi t in otherwise-healthy people with mildly elevated TSH values.
Various professional societies have adopted different criteria for aggressive case-fi nding in patients at risk of thyroid disease. Risk factors include family history of thyroid disease, neck irradiation, partial thyroidectomy, dyslipidemia, atrial fi brillation, unexplained weight loss, hyperprolactinemia, autoimmune disorders, and use of medications affecting thyroid function.
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The US Preventive Services Task Force
Reverts to euthyroid state in up to 60% of cases over 5 years, depending on serum TSH concentration and antithyroid antibody status.
Progresses to overt hypothyroidism in 1%-5% of cases per year, depending on serum TSH concentration and antithyroid antibody status. 
Cardiovascular endothelial dysfunction
Increased risk of myocardial infarction, atherosclerosis, aortic calcifi cation, 48 cardiovascular disease and mortality
37
; increased arterial stiffness and systemic vascular resistance 45, 53 Lessens cardiovascular risk and mortality in patients < 65 years
Stroke
Confl icting data: no association in patients ≥ 65 years, but some association in those < 65
Lessens cardiovascular risk and mortality in patients < 65 years
Psychiatric and cognitive dysfunction
Associated with worsened preexisting depression and bipolar disease; may affect cognition 65 May improve mood, anxiety, cognition in older patients Too few clinical studies to defi ne a role
Thyroid cancer
Some data suggest elevated TSH is associated with higher risk [79] [80] [81] [82] More studies needed to understand association
Infertility, recurrent miscarriage
Inconclusive evidence links subclinical hypothyroidism with infertility 86 ; infertility rate is higher in women who also have positive thyroid peroxidase antibody than in women without autoimmunity 87 Some studies have shown lower rates of miscarriage with levothyroxine when TSH > 4.0 mIU/L 86, [91] [92] ; insuffi cient data to support its use in patients with subclinical hypothyroidism and infertility; however, consider in euthyroid patients with positive peroxidase antibody and recurrent miscarriage 90 Pregnancy complications Associated with several pregnancy-related complications including preeclampsia, hypertension, placental abruption, and postpartum hemorrhage in some studies, 26, 96 but not in others; if present, screen for autoimmunity No recommendations; insuffi cient evidence to evaluate role of treatment
Preterm delivery, pregnancy loss
Associated with high risk of miscarriage, preterm delivery, pregnancy loss at even mildly elevated TSH levels (2.5-5 mIU/L) 99;104-107 ; risk is as high as 60% with TSH levels > 6 mIU/L and higher with positive thyroid peroxidase antibody [108] [109] [110] Improves maternal and fetal outcomes, including risk of low birth weight and low Apgar score, in women with subclinical hypothyroidism and TSH 2.5-10 mIU/L 93, 106 ; evidence less clear with TSH 2.5-4 mIU/L 86 ; not recommended for the subgroup of pregnant patients with negative thyroid peroxidase antibody and TSH within pregnancy-specifi c range or < 4 mIU/L AZIM AND NASR in 2014 found insuffi cient evidence on the benefi ts and harms of screening.
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The American Thyroid Association (ATA) recommends screening adults starting at age 35, with repeat testing every 5 years in patients who have no signs or symptoms of hypothyroidism, and more frequently in those who do.
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The
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The American Academy of Family Physicians recommends screening after age 60.
18
The American College of Physicians recommends screening patients over age 50 who have symptoms.
Our approach. Although evidence is lacking to recommend routine screening in adults, aggressive case-fi nding and treatment in patients at risk of thyroid disease can, we believe, offset the risks associated with subclinical hypothyroidism.
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■ CLINICAL PRESENTATION About 70% of patients with subclinical hypothyroidism have no symptoms.
13
Tiredness was more common in subclinical hypothyroid patients with TSH levels lower than 10 mIU/L compared with euthyroid controls in 1 study, but other studies have been unable to replicate this fi nding.
27,28
Other frequently reported symptoms include dry skin, cognitive slowing, poor memory, muscle weakness, cold intolerance, constipation, puffy eyes, and hoarseness. 13 The evidence in favor of levothyroxine therapy to improve symptoms in subclinical hypothyroidism has varied, with some studies showing an improvement in symptom scores compared with placebo, while others have not shown any benefi t.
29-31
In one study, the average TSH value for patients whose symptoms did not improve with therapy was 4.6 mIU/L. 31 An explanation for the lack of effect in this group may be that the TSH values for these patients were in the high-normal range. Also, because most subclinical hypothyroid patients have no symptoms, it is diffi cult to ascertain symptomatic improvement. Though it is possible to conclude that levothyroxine therapy has a limited role in this group, it is important to also consider the suggestive evidence that untreated subclinical hypothyroidism may lead to increased morbidity and mortality.
■ ADVERSE EFFECTS OF SUBCLINICAL HYPOTHYROIDISM, EFFECTS OF THERAPY
Subclinical hypothyroidism has been associated with adverse metabolic, cardiovascular, neuromuscular, and cognitive effects and has been shown to have a detrimental impact on quality of life. However, studies of levothyroxine therapy in subclinical hypothyroidism have yielded mixed results. 16 Subclinical hypothyroidism affects many biologic systems, and levothyroxine may have a role ( Table 2) .
32-117
■ INDIVIDUALIZED MANAGEMENT AND SHARED DECISION-MAKING
The management of subclinical hypothyroidism should be individualized on the basis of Shared decision-making is key, weighing the risks and benefi ts of levothyroxine treatment and the patient's goals. There is some evidence to support levothyroxine treatment in nonpregnant patients with overt hypothyroidism (TSH > 10 mIU/L) or in patients with TSH 5 to 10 mIU/L with symptoms or hyperlipidemia and in younger patients at risk of cardiovascular disease.
118 Table 3 describes various patient factors that should be considered during clinical evaluation and decisions about levothyroxine treatment in subclinical hypothyroidism.
The risks of treatment should be kept in mind and explained to the patient. Levothyroxine has a narrow therapeutic range, causing a possibility of overreplacement, and a half-life of 7 days that can cause dosing errors to have longer effect. 118, 119 Adherence can be a challenge. The drug needs to be taken on an empty stomach because foods and supplements interfere with its absorption. 118, 120 In addition, the cost of medication, frequent biochemical monitoring, and possible need for titration can add to fi nancial burden. 
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When choosing the dose, one should consider the degree of hypothyroidism or TSH elevation and the patient's weight, and adjust the dose gently.
If the TSH is high-normal
It is proposed that a TSH range of 3 to 5 mIU/L overlaps with normal thyroid function in a great segment of the population, and at this level it is probably not associated with clinically signifi cant consequences. For these reasons, levothyroxine therapy is not thought to be benefi cial for those with TSH in this range.
Pollock et al 121 found that, in patients with symptoms suggesting hypothyroidism and TSH values in the upper end of the normal range, there was no improvement in cognitive function or psychological well-being after 12 weeks of levothyroxine therapy.
However, due to the concern for possible adverse maternal and fetal outcomes and low IQ in children of pregnant patients with subclinical hypothyroidism, levothyroxine therapy is advised in those who are pregnant or planning pregnancy who have TSH levels higher than 2.5 mIU/L, especially if they have thyroid peroxidase antibody. Levothyroxine therapy is not recommended for pregnant patients with negative thyroid peroxidase antibody and TSH within the pregnancy-specifi c range or less than 4 mIU/L if the reference ranges are unavailable.
Keep in mind that, even at these TSH values, there is risk of progression to overt hypothyroidism, especially in the presence of thyroid peroxidase antibody, so patients in this group should be monitored closely.
If TSH is mildly elevated
The evidence to support levothyroxine therapy in patients with subclinical hypothyroidism with TSH levels less than 10 mIU/L remains inconclusive, and the decision to treat should be based on clinical judgment. 2 The studies that have looked at the benefi t of treating subclinical hypothyroidism in terms of cardiac, neuromuscular, cognitive, and neuropsychiatric outcomes have included patients with a wide range of TSH levels, and some of these studies were not stratifi ed on the basis of degree of TSH elevation.
The risk that subclinical hypothyroidism will progress to overt hypothyroidism in patients with TSH higher than 8 mIU/L is high, and in 70% of these patients, the TSH level rises to more than 10 mIU/L within 4 years. Early treatment should be considered if the TSH is higher than 7 or 8 mIU/L.
If TSH is higher than 10 mIU/L
The strongest evidence in favor of treating subclinical hypothyroidism is in patients with TSH levels higher than 10 mIU/L. 2 Thyroid dysfunction with this degree of TSH elevation has been associated with adverse cardiometabolic, neuromuscular, cognitive, and psychiatric effects as described above, and has been shown to improve with levothyroxine therapy. 
